Table 5 The demographic and clinical characteristics of the participants
From: Real-life experiences with galcanezumab and predictors for treatment response in Turkey
Variables | Non-responsive n (%) | 50–74% of responsiveness n (%) | 75–99% of responsiveness n (%) | Headache freedom n (%) |
|---|---|---|---|---|
All patients (n = 476) | 64 (13.6) | 129 (27.1) | 215 (45.3) | 68 (14.0) |
Females (n = 384) | 46 (12.0) | 103 (26.8) | 179 (46.6) | 56 (14.6) |
Males (n = 92) | 18 (19.6) | 26 (28.3) | 36 (39.1) | 12 (13.0) |
EM (n = 241) | 28 (11.6) | 62 (25.7) | 107 (44.4) | 44 (18.3) |
LFEM (n = 79) | 10 (12.7) | 23 (29.1) | 33 (41.8) | 13 (16.5) |
HFEM (n = 145) | 17 (11.7) | 39 (26.9) | 65 (44.8) | 24 (16.6) |
CM (n = 235) | 36 (15.6) | 67 (28.5) | 108 (46.0) | 24 (10.2) |
CM w/o MOH (n = 31) | 8 (25.8) | 8 (25.8) | 13 (41.9) | 2 (6.5) |
CM with MOH (n = 204) | 28 (13.7) | 59 (28.9) | 95 (46.6) | 22 (1.8) |
MwoA (n = 324) | 42 (13.0) | 90 (27.8) | 146 (45.1) | 46 (14.2) |
MwA (n = 152) | 22 (14.5) | 39 (25.7) | 69 (45.4) | 22 (14.5) |
Age of 18–34 (n = 106) | 15 (14.2) | 39 (36.8) | 38 (35.8) | 14 (13.2) |
Age of 35–49 (n = 236) | 31 (13.1) | 55 (23.3) | 120 (50.8) | 30 (12.7) |
Age of 50–64 (n = 121) | 15 (12.4) | 32 (26.4) | 53 (43.)8 | 21 (17.4) |
Age of > 65 (n = 13) | 3 (23.1) | 3 (23.1) | 4 (30.8) | 3 (23.1) |
≤ 2 PPTF (n = 297) | 28 (9.4) | 73 (24.6) | 142 (47.8) | 54 (18.2) |
≥ 3 PPTF (n = 179) | 36 (20.1) | 56 (31.3) | 73 (40.8) | 14 (7.8) |